Affimed AFMD 深 滬
交易中 09-20 10:33:22 美东时间
3.89
-0.070
-1.77%
華盛通- 最 高3.9449
- 今 開3.90
- 成交量 3.44万股
- 最 低 3.87
- 昨 收 3.96
- 總市值 5809.29万
- 52周最高 8.95
- 市盈率 靜 --
- 換手率 0.23%
- 52周最低 2.235
- 委 比 50.00%
- 總股本 1493.39万
- 歷史最高 242.00
- 量 比 3.74
- 振 幅 1.89%
- 歷史最低 2.235
- 每 手 1
- 風險率 0.91%
個股概要
財務分析
公司資料
相關新聞
分紅派息
- 分時圖
- 日k
- 周k
- 月k
相關新聞
更多Affimed N.V. Announces Upcoming EGM
Affimed (AFMD) has released an update. Affimed N.V. invites shareholders to an ...
09-11 19:57
Affimed N.V. Faces Substantial Mid-Year Losses
Affimed (AFMD) has released an update. Affimed N.V. reports a significant opera...
09-05 18:57
Affimed GAAP EPS of -€1.01, revenue of €0.2M
Affimed press release (NASDAQ:AFMD): Q2 GAAP EPS of -€1.01. Revenue of €0.2M (-85.7% Y/Y). As of June 30, 2024, cash, cash equivalents and investments were €34.4 million. Based on operating and financ...
09-05 18:31
Affimed Appoints New CEO to Bolster Growth
Affimed (AFMD) has released an update. Affimed N.V., a clinical-stage oncology ...
09-03 20:28
Affimed appoints Shawn Leland as chief executive officer
Affimed N.V. (NASDAQ:NASDAQ:NASDAQ:NASDAQ:AFMD) has announced that Shawn M. Leland, PharmD, RPh has been appointed as Chief Executive Officer (CEO). Dr. Andreas Harstrick, acting CEO since January 20...
09-03 19:58
Artiva Biotherapeutics surges on trading debut
Artiva Biotherapeutics (ARTV) climbed ~25% from its initial public offering price as the cell therapy developer made its public trading debut on Friday. Following an IPO priced at $12.00 apiece, ARTV ...
07-20 01:16
Cell therapy developer Artiva refiles for a $100M IPO
Cell therapy developer Artiva Biotherapeutics (ARTV), whose collaborators include German biotech Affimed (AFMD), has filed with the SEC to raise up to $100M in an initial public offering under the tic...
06-29 22:07
Affimed (AFMD) Gets a Buy from Truist Financial
In a report released yesterday, Srikripa Devarakonda from Truist Financial main...
06-18 10:25
Affimed Analyst Ratings
Unity Software(U.US) reported fourth-quarter financial results after the market...
06-13 05:16
Affimed reports Q1 results
Affimed press release (NASDAQ:AFMD): Q1 total revenue was €0.2 million compared with €4.5 million for the quarter ended March 31, 2023. Net loss was €19.2 million, or €1.27 loss per common share. More...
06-12 18:39
